REGISTRATION NO. 333-82667
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM S-1/A
Post-effective Amendment No. 1
-------------------------
GENEREX BIOTECHNOLOGY CORPORATION
(Name of Issuer in Its Charter)
<TABLE>
<S> <C> <C>
Delaware 2834 82-0490211
(State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer
incorporation or organization) Classification Code Number) Identification No.)
</TABLE>
33 Harbour Square, Suite 202
Toronto, Ontario
CANADA M5J 2G2
Telephone: 416/364-2551
Facsimile: 416/364-9363
Anna E. Gluskin, CEO and President
33 Harbour Square, Suite 202
Toronto, Ontario
CANADA M5J 2G2
Telephone: 416/364-2551
Facsimile: 416/364-9363
(Name, address and telephone number of agent for service)
-------------------------
Copies to:
Joseph Chicco, Esquire
Eckert Seamans Cherin & Mellott, LLC
1515 Market Street - 9th Floor
Philadelphia, PA 19102
Telephone: 215/851-8410
Facsimile: 215/851-8383
-------------------------
Approximate date of commencement of proposed sale to the public: November 19,
1999
If any of the securities being registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the box. [x]
If this Form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, please check the following box and list
the Securities Act registration statement number of the earlier effective
registration statement for the same offering [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
<PAGE>
REMOVAL FROM REGISTRATION
Pursuant to the undertaking set forth in Item 27 of this Registration Statement,
Generex Biotechnology Corporation (the "Registrant") hereby removes from
registration under the Registration Statement all securities registered hereby
that remain unsold.
<PAGE>
SIGNATURES
In accordance with the requirements of the Securities Act of 1933, we
certify that we have authorized this Post-effective Amendment to the
Registration Statement to be signed on our behalf by the undersigned, our
President, on the 13th day of June, 2000.
GENEREX BIOTECHNOLOGY CORPORATION
By: /s/ Anna E. Gluskin
--------------------------
Anna E. Gluskin, President
SIGNATURES
In accordance with the requirements of the Securities Act of 1933, this
Post-effective Amendment to the Registration Statement was signed by the
following persons in the capacities and on the dates stated.
<TABLE>
<CAPTION>
Signatures Title Date
---------- ----- ----
<S> <C> <C>
/s/ Anna E. Gluskin
-------------------
Anna E. Gluskin President, Chief Executive Officer and June 13, 2000
Director
/s/ E. Mark Perri
-------------------
E. Mark Perri Chairman of the Board, Chief Financial June 13, 2000
Officer and Director
/s/ Rose C. Perri
-------------------
Rose C. Perri Director June 13, 2000
/s/ Pankaj Modi
-------------------
Pankaj Modi, Ph.D. Director June 13, 2000
</TABLE>
